BioSpace News Archive

Ultragenyx Pharmaceutical Inc. announced positive longer-term efficacy and safety data from Phase 1/2 studies of DTX401 for the potential treatment of Glycogen Storage Disease Type Ia and DTX301 for the potential treatment of Ornithine Transcarbamylase deficiency.

Biomea Fusion, Inc. (Nasdaq: BMEA), announced the nomination of its second product candidate, BMF-500, a highly selective and potent covalent investigational third-generation FLT3 inhibitor.

Centerline Biomedical, Inc. announced Thursday the completion of the second in a series of structural heart navigation animal studies.

Azenta, Inc. announced that Company management will participate in the UBS Global Healthcare Conference in New York, on Tuesday, May 24, 2022, which includes a presentation beginning at 2:45 pm ET.

Axcella Therapeutics announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23 – 26, 2022 both virtually and in-person in Miami, Florida.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that health economics and outcomes research (HEOR) comparing the cost-effectiveness of the Company’s 3-antigen hepatitis B vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], to a single-antigen HBV vaccine, Engerix-B®, among adults.

ProgenaCare Global ™ LLC., the developer and manufacturer of the only human keratin matrix, ProgenaMatrix®, approved for use in acute and chronic wounds, has announced the addition of Howard Walthall as Chief Executive Officer.

Applied UV, Inc. (NasdaqCM: AUVI ) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that Monica Woo has joined the Board of Directors.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Toro Lateral (Toro-L) Interbody Fusion System.

Saint Herblain, May19, 2022 – Valneva SE, a specialty vaccine company, confirmed that the European Medicines Agency has accepted the filing of a marketing authorization application for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.